Main Line pharma company plans key study of Fragile X syndrome therapy
Zynerba Pharmaceuticals said Monday it plans — with the Food and Drug Administration's approval — to initiate a single pivotal study later this year to support a new drug application for its experimental cannabis-based treatment for Fragile X Syndrome.
Fragile X is a rare genetic developmental disability that is a leading known cause of b oth inherited intellectual disability and autism spectrum disorder. It affects an estimated one in 3,600 to 4,000 males and one in 4,000 to 6,000 females.…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: John George Source Type: news
More News: Autism | Disability | Food and Drug Administration (FDA) | Fragile X Syndrome | Genetics | Health Management | New Drug Applications | Pharmaceuticals | Study